EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease

Weronika Frąk iD, Bartłomiej Dąbek iD, Marta Balcerczyk-Lis, Jakub Motor iD, Ewa Radzioch iD, Ewelina Młynarska iD, Jacek Rysz, Beata Franczyk

Antioxidants · 03.06.2024 · 13 (6) · 687

DOI: 10.3390/antiox13060687 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 03.06.2024. Verfasst von Weronika Frąk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrocardiology, Medical Univeristy of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Affecting millions of people worldwide, chronic kidney disease is a serious medical problem. It results in a decrease in glomerular filtration rate below 60 mL/min/1.73 m, albuminuria, abnormalities in urine sediment and pathologies detected by imaging studies lasting a minimum of 3 months. Patients with CKD develop uremia, and as a result of the accumulation of uremic toxins in the body, patients can be expected to suffer from a number of medical consequences such as progression of CKD with renal fibrosis, development of atherosclerosis or increased incidence of cardiovascular events. Another key element in the pathogenesis of CKD is oxidative stress, resulting from an imbalance between the production of antioxidants and the production of reactive oxygen species. Oxidative stress contributes to damage to cellular proteins, lipids and DNA and increases inflammation, perpetuating kidney dysfunction. Additionally, renal fibrogenesis involving the accumulation of fibrous tissue in the kidneys occurs. In our review, we also included examples of forms of therapy for CKD. To improve the condition of CKD patients, pharmacotherapy can be used, as described in our review. Among the drugs that improve the prognosis of patients with CKD, we can include: GLP-1 analogues, SGLT2 inhibitors, Finerenone monoclonal antibody—Canakinumab and Sacubitril/Valsartan.

Schlagwörter

Stichwörter der Autor:innen

chronic kidney diseaseoxidative stressrenal fibrosistreatmenturemic toxins

Autor:innen und Institutionen

  • Department of Nephrocardiology, Medical Univeristy of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
  • Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.

ORCID-Profile: Weronika Frąk, Bartłomiej Dąbek, Jakub Motor, Ewa Radzioch, Ewelina Młynarska

Zitieren

APA

Frąk, W., Dąbek, B., Balcerczyk-Lis, M., Motor, J., Radzioch, E., Młynarska, E., Rysz, J., & Franczyk, B. (2024). Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease. Antioxidants, 13(6), 687. https://doi.org/10.3390/antiox13060687

Vancouver

Frąk W, Dąbek B, Balcerczyk-Lis M, Motor J, Radzioch E, Młynarska E, et al. Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease. Antioxidants. 2024;13(6):687. doi:10.3390/antiox13060687

BibTeX
@article{Frk2024,
  author = {Frąk, Weronika and Dąbek, Bartłomiej and Balcerczyk-Lis, Marta and Motor, Jakub and Radzioch, Ewa and Młynarska, Ewelina and Rysz, Jacek and Franczyk, Beata},
  title = {Role of Uremic Toxins, Oxidative Stress, and Renal Fibrosis in Chronic Kidney Disease},
  journal = {Antioxidants},
  year = {2024},
  volume = {13},
  number = {6},
  pages = {687},
  doi = {10.3390/antiox13060687}
}
Kostenlos starten →